Abstract 72P
Background
Recent and detailed data regarding treatment quality of patients with AOC in the era of precision medicine are largely unknown in Germany.
Methods
All German hospitals treating patients with ovarian cancer were asked to document prospectively all patients with first diagnosis in the third quarter in 2021. Details of tumor, treatment and outcome were documented. Here, we report tumor and treatment characteristics.
Results
In total, 598 pts with AOC were documented. The primary debulking surgery (PDS) rate was 429/598 (71.7%) and complete resection (CR) at PDS was achieved in 252/429 pts (58.7%), 92/598 pts (15.4%) had interval debulking surgery and 77/598 pts (12.9%) had no surgery. In total, 514/598 pts (86.0%) were treated with chemotherapy. 490/514 (95.3%) received carboplatin/paclitaxel and 401/514 (78.0%) received additional maintenance therapy. 470 patients had high-grade histology and were treated with chemotherapy. The BRCA testing rate in this population was 390/470 (83.0%) and HRD testing rate was 245/470 (52.1%). In total, 90 of 390 tested patients were BRCA-positive (23.1%) and 101/245 patients were HR deficient (41.2%). BRCA+ patients were treated with bevacizumab/PARPi in 58.9%, PARPi single agent in 31.1%. The rates in BRCAwt/HRd were 62.9% and 12.0%, respectively. HRp tumors were treated mainly with bevacizumab (70.8%) or by PARPi in 15.4%. BRCAwt/HRD unknown patients were treated mainly with bevacizumab (35.8%) or PARPi (30.5%). Patients who were not tested (15.8%) were mainly treated with chemotherapy only (58.0%) and bevacizumab (35.8%). The rates of chemo only patients in the other subgroups varied between 2.2% and 22.1%.
Conclusions
Most patients in Germany with AOC are treated with primary surgery followed by chemotherapy including a maintenance therapy. The rates of BRCA and HRD testing are high and PARPi in primary OC are often used already after a short period after approval in Germany.
Legal entity responsible for the study
AGO Research GmbH (AGO Study Group).
Funding
AstraZeneca, GSK.
Disclosure
P. Harter: Financial Interests, Personal, Advisory Board, Value includes honoraria for lectures: AstraZeneca; Financial Interests, Personal, Advisory Board, includes honoraria for lectures: GSK, Roche, MSD; Financial Interests, Personal, Invited Speaker: Amgen, Stryker, Zailab, Eisai; Financial Interests, Personal, Advisory Board: Clovis, Immunogen, Novartis, Mersana, Miltenyi; Financial Interests, Personal, Other, IDMC member: Sotio; Financial Interests, Personal, Expert Testimony: Exscientia; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche, GSK, Genmab, Immunogen; Financial Interests, Institutional, Funding: Seagen, Clovis; Financial Interests, Institutional, Other, Co-investigator: Novartis; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca; Other, Personal, Other, Travel support for conference: AstraZeneca. J. Pfisterer: Financial Interests, Personal, Advisory Board: Roche, Amgen, AstraZeneca, GSK; Financial Interests, Institutional, Invited Speaker: Roche, GSK. A. Du Bois: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK / Tesaro; Financial Interests, Personal, Invited Speaker: Zodiac. S. Mahner: Financial Interests, Personal, Advisory Board, Honoraria & reimbursement: AbbVie, AstraZeneca, Clovis, Eisai, Novartis, Olympus, Seagen; Financial Interests, Personal, Invited Speaker, Honoraria & reimbursement: GSK, MSD, Pfizer, Roche, Tesaro, Hubro, Nykode; Financial Interests, Institutional, Research Grant: AstraZeneca, Eisai, GSK, MSD, Roche, Tesaro. F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/immunomedics, Eisai, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Seagen, Daiichi Sankyo, GSK, AstraZeneca, Stemline Menarini, Roche, AstraZeneca, Novartis, Roche, Eisai, Gilead/Immunomedics, MSD, German Breast Group, AGO Research GmbH, Vaccibody, GSK; Financial Interests, Institutional, Advisory Board: Roche, Immunicom; Financial Interests, Institutional, Funding: AstraZeneca, Lilly, Seagen. M. Kerkmann: Financial Interests, Personal, Full or part-time Employment: MMF GmbH; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Amgen, Bristol Myers Squibb, Janssen-Cilag, Pharmacosmos, MSD, Takeda; Non-Financial Interests, Personal, Member: Working Group Medical Oncology (AIO) of the German Cancer Society (DKG), Working Group Supportive Care (AGSMO) of the German Cancer Society (DKG), German Cancer Society (DKG). J. Sehouli: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, MSD, Tesaro, ImmunoGen, Tubulis, Novocure, Incyte; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Institutional, Funding: Roche, GSK, AstraZeneca; Financial Interests, Institutional, Invited Speaker: Novocure; Non-Financial Interests, Institutional, Proprietary Information: ENGOT/NOGGO; Non-Financial Interests, Personal, Leadership Role, Council Member: ESGO; Non-Financial Interests, Personal, Leadership Role: North-Eastern German Society of Gynecological Oncology (NOGGO), Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO), Pab-Arabian Research Society of Gynecological Oncology (PARSGO). N. De Gregorio: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Myriad, Novartis, MSD, GSK, Clovis, Gilead; Other, Personal, Other, travel expenses: AstraZeneca, Gilead. L.C. Hanker: Financial Interests, Personal, Advisory Board: Amgen, Roche, GSK, MSD, AstraZeneca, Eisai, Novartis, Immunogen. F. Heitz: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, GSK, NovoCure; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK. L. Woelber: Financial Interests, Personal, Advisory Board: GSK, Roche, MSD, Eisai, Seagen, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, MSD, Seagen, AstraZeneca, Novartis; Financial Interests, Personal, Other, scientific board: med update GmbH; Financial Interests, Personal, Other, speaker: med publico GmbH; Financial Interests, Institutional, Invited Speaker: Seagen, MSD, medac oncology, Vaccibody AS, Roche; Non-Financial Interests, Institutional, Product Samples: Roche diagnostics; Non-Financial Interests, Personal, Leadership Role, current president: ECSVD; Non-Financial Interests, Personal, Leadership Role: AGO study group, AGO commission vulva vagina. L. Holtmann: Financial Interests, Personal, Full or part-time Employment: MMf GmbH; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Bristol Myers-Squibb, Janssen-Cilag, MSD, Pharmacosmos, Roche, Takeda. G. Elser: Other, Personal, Other, Employee: AGO Research GmbH. F. Hilpert: Financial Interests, Personal, Advisory Board: MSD, Immunogen; Financial Interests, Personal, Invited Speaker: MSD, GSK, AstraZeneca, Novartis.